Avandaryl for first- and second-Line treatment of type 2 diabetes

The Korea Food and Drug Administration said it has approved GlaxoSmithKline's Avandaryl for use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus who are already receiving rosiglitazone plus a sulfonylurea or who are not adequately controlled on either drug alone.

Avandaryl (rosiglitazone maleate and glimepiride), a new fixed-dose combin...